

## Product Data Sheet

Product Name: HEC96719

Cat. No.: GC73416

### Chemical Properties

Cas. No. 2181834-03-5


Formula  $C_{29}H_{22}Cl_2N_2O_5$  M.Wt 549.4

Solubility DMSO : 100 mg/mL (182.02 mM; Storage -20°C  
Need ultrasonic)

General tips For obtaining a higher solubility , please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request.

Structure



### Background

HEC96719 is a selective and orally active tricyclic farnesoid X receptor (FXR) agonist with EC50 values of 1.37 and 1.55 nM by time-resolved fluorescence energy transfer (TR-FRET) and luciferase reporter assays, respectively. HEC96719 significantly improves non-alcoholic steatohepatitis (NASH) and liver fibrosis with favorable tissue distribution in liver and intestine. HEC96719 can be used for the research of non-alcoholic steatohepatitis.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

## Product Data Sheet

---

HEC96719 (0.5, 1.5 and 5 mg/kg; oral administration, once daily for 14 days) shows in vivo efficacy for the activation of FXR by measuring the increasing level of fibroblast growth factor 15 (FGF15) [1]. HEC96719 (5 mg/kg; oral administration, once) increases the level of liver bile salt export pump (BSEP) and ileum FGF15 [1]. HEC96719 (0.1, 0.3 and 1 mg/kg; oral administration, once daily for 6 weeks) significantly improves NASH symptoms [1]. HEC96719 (0.1, 0.3 and 1 mg/kg; oral administration, once daily for 4 weeks) shows efficacy for improving liver fibrosis and has better effects than obeticholic acid (OCA) [1].

### References:

[1]. Cao S, et al. Discovery of a tricyclic farnesoid X receptor agonist HEC96719, a clinical candidate for treatment of non-alcoholic steatohepatitis. *Eur J Med Chem.* 2022 Feb 15;230:114089.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: [tech@glpbio.com](mailto:tech@glpbio.com)

Address: 10292 Central Ave. #205, Montclair, CA, USA